Canine Cushing's Forums  

Go Back   Canine Cushing's Forums > Important Information and Resources


Closed Thread
Thread Tools Search this Thread Display Modes
Old 08-29-2002, 05:53 AM
Posts: n/a
Default Study on Trilostane

For anyone who is interested in information about Trilostane which is sold in the UK under the brand name "Vetoryl" (and also sold as "Modrenal") ... and which is an approved treatment in the UK for Canine Cushing's, I'm posting this study here for anyone who is interested.

This is an abstract for a study on Trilostane which was presented at the American College of Veterinary Internal Medicine Conference in the year 2000, but the study was done at the Royal Vet College, University of London prior to 2000.

Here's a link to the Webpage where I found it..

(It is abstract # 195 on that page)

and I'll also copy and paste it for you here below...



Commonly used therapeutic agents for canine hyperadrenocorticism (HAC) may be only partially effective or have undesirable and potentially life-threatening side effects. The efficacy and long term safety of trilostane, a synthetic inhibitor of adrenal steroidogenesis, was evaluated in 30 dogs (age: mean 9.0 (SD ± 2.8 ) years; 14 male; weight: mean 20.5 (SD ± 13.8 ) kg) with confirmed HAC. Initial diagnoses was based on typical clinical signs, and biochemical abnormalities and an ACTH-stimulation test (n=28 ) and/or low-dose dexamethasone suppression test (n=15). Three dogs had an adrenal tumour confirmed by abdominal ultrasound; surgery was performed in one. Re-evaluation occurred after 10, 30-40, 60-90 days and thereafter at 3-4 monthly intervals and an ACTH-stimulation test was performed each time. Initial trilostane dose was based on body weight and was adjusted upon resolution of clinical signs and the ACTH-stimulation test.

Polydipsia (n=27) and polyphagia (n=14) abated within days starting trilostane in all dogs. Dermatological signs, pendulous abdomen or exercise intolerance improved over a longer period of time. 18 dogs are alive after a mean of 366 days (range: 70-730) while 12 dogs are dead after a mean of 287 days (range: 30-630) (adrenal tumour dogs after 630, 390 & 300 days). Mean initial trilostane dose was 6.1 (SD ± 3.3) mg/kg. Based on clinical signs and ACTH-stimulation test, trilostane dose was adjusted to 7.3 (SD ± 5.3) mg/kg. While initial ACTH-stimulation test was indicative of HAC in 19 dogs with a mean stimulated cortisol of 850 (SD ± 370) nmol/l (normal: <600 nmol/l), stimulated cortisol was in the normal range in all re-evaluations of all dogs except one ACTH-stimulation test of a dog with an adrenal tumour (mean ± SD stimulated cortisol: 10 days: 251 ± 157.5 nmol/l; 30-40 days: 214 ± 155.6 nmol/l; 60-90 days: 285 ± 244.4 nmol/l).

Trilostane was stopped altogether due to spontaneous resolution of HAC in 3 dogs and for a few days due to a flat response of the ACTH-stimulation test in one dog. Two dogs developed hyperkalemia which normalised without intervention after stopping trilostane. Of two dogs with a Na:K-ratios < 24, one developed severe arrhythmia and one had an uncontrollable urinary tract infection; trilostane was stopped in both but one was euthanised and one died shortly thereafter. In conclusion, trilostane seems to be an effective and safe treatment option in the long run for dogs with HAC.
Closed Thread

Thread Tools Search this Thread
Search this Thread:

Advanced Search
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is Off
HTML code is Off

All times are GMT -5. The time now is 11:34 PM.

Powered by vBulletin® Version 3.7.3
Copyright ©2000 - 2020, Jelsoft Enterprises Ltd.